Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome — IVL for OHS  

Ocular Histoplasmosis Syndrome Clinical Trial

Official title: Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization in Ocular Histoplasmosis Syndrome

Status Unknown status

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of intravitreal ranibizumab (Lucentis) in patients with fluid and blood leakage in their eyes due to ocular histoplasmosis.

Clinical Trial Description

Patients will be evaluated monthly for one year.

Participants will be assigned to one of two groups:

Group A will receive 3 monthly injections of ranibizumab followed by an as needed injection throughout the remainder of the study Group B will receive injections of ranibizumab on an as needed basis throughout the study

You cannot take part in this study if:

1. You are pregnant or intending to become pregnant in the next 12 months or are nursing an infant

2. You are under the age of 18 ;

Related Conditions & MeSH terms

• Choroidal Neovascularization
• Histoplasmosis
• Neovascularization, Pathologic
• Ocular Histoplasmosis Syndrome
• Syndrome

• NCT number: NCT00955630
• Study type: Interventional
• Source: Retina Associates of Kentucky
• Contact: Diana Holcomb, COA
• Phone: 859-263-3900
• Email: dholcomb@retinaky.com
• Status: Unknown status
• Phase: Phase 1/Phase 2
• Start date: August 2009